"Carcinoembryonic Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
| Descriptor ID |
D002272
|
| MeSH Number(s) |
D12.776.395.550.200.210 D12.776.543.550.200.210 D23.050.285.329 D23.050.301.350.210 D23.101.140.300
|
| Concept/Terms |
Carcinoembryonic Antigen- Carcinoembryonic Antigen
- Antigen, Carcinoembryonic
- CD66e Antigen
- Antigens, CD66e
- CD66e Antigens
- Antigen, CD66e
|
Below are MeSH descriptors whose meaning is more general than "Carcinoembryonic Antigen".
Below are MeSH descriptors whose meaning is more specific than "Carcinoembryonic Antigen".
This graph shows the total number of publications written about "Carcinoembryonic Antigen" by people in this website by year, and whether "Carcinoembryonic Antigen" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 2 | 3 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 6 | 6 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 1 | 5 | 6 |
| 2007 | 1 | 3 | 4 |
| 2008 | 4 | 3 | 7 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 3 | 4 |
| 2011 | 2 | 3 | 5 |
| 2012 | 5 | 1 | 6 |
| 2013 | 5 | 2 | 7 |
| 2014 | 6 | 2 | 8 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 5 | 7 |
| 2018 | 7 | 2 | 9 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
Below are the most recent publications written about "Carcinoembryonic Antigen" by people in Profiles.
-
CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. J Nucl Med. 2024 Jul 01; 65(7):1043-1050.
-
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody. Ann Surg Oncol. 2024 Sep; 31(9):6291-6299.
-
Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models. J Surg Res. 2024 01; 293:701-708.
-
Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
-
Neutrophil CEACAM1 determines susceptibility to NETosis by regulating the S1PR2/S1PR3 axis in liver transplantation. J Clin Invest. 2023 02 01; 133(3).
-
Accurate Identification of Mucinous Pancreatic Cystic Lesions Using Small-Volume Analytes. J Surg Res. 2023 04; 284:322-331.
-
Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet. Anticancer Res. 2022 Aug; 42(8):3857-3861.
-
Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
-
The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review. Biomolecules. 2021 Dec 02; 11(12).
-
Necessity of posttreatment surveillance for low-grade appendiceal mucinous neoplasms. J Surg Oncol. 2021 Dec; 124(7):1115-1120.